HWM
TLSI icon

HighMark Wealth Management’s TriSalus Life Sciences TLSI Stock Holding History

HighMark Wealth Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
48,300
+15,000
+45% +$59.6K 0.07% 79
2026
Q1 		$133K Buy
33,300
+22,500
+208% +$110K 0.05% 95
2025
Q4 		$75.4K Buy
+10,800
New +$60.5K 0.03% 126

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

HighMark Wealth Management's TLSI Position: Q2 2026 in Review

HighMark Wealth Management increased its TriSalus Life Sciences (TLSI) stake by 45% in Q2 2026, buying an estimated $59.6K and bringing the position to 48,300 shares worth $220K. The position accounts for 0.07% of the portfolio, ranked #79.

HighMark Wealth Management first reported a position in TLSI in Q4 2025 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • HighMark Wealth Management held 48,300 shares of TriSalus Life Sciences worth $220K as of Q2 2026.
  • HighMark Wealth Management bought 15,000 TriSalus Life Sciences shares in Q2 2026, an estimated $59.6K.
  • TriSalus Life Sciences made up 0.07% of HighMark Wealth Management's portfolio in Q2 2026, its #79 holding.
  • HighMark Wealth Management first reported a position in TriSalus Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.